US 12,247,015 B2
3-amino-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2
Simone Bigi, San Diego, CA (US); Alison L. Chambers, San Diego, CA (US); Tony Gibson, San Diego, CA (US); Jason Pickens, San Diego, CA (US); Steve Swann, San Diego, CA (US); Angie Vassar, San Diego, CA (US); Feng Zhou, San Diego, CA (US); Mitsunori Kono, Kanagawa (JP); Masaki Seto, Kanagawa (JP); and Zenyu Shiokawa, Kanagawa (JP)
Assigned to SOLENT THERAPEUTICS, LLC, Palo Alto, CA (US)
Appl. No. 17/605,962
Filed by Solent Therapeutics, LLC, Wellesley, MA (US)
PCT Filed Apr. 28, 2020, PCT No. PCT/US2020/030305
§ 371(c)(1), (2) Date Oct. 22, 2021,
PCT Pub. No. WO2020/223255, PCT Pub. Date Nov. 5, 2020.
Claims priority of provisional application 62/840,344, filed on Apr. 29, 2019.
Prior Publication US 2022/0119361 A1, Apr. 21, 2022
Int. Cl. C07D 285/24 (2006.01); C07D 417/10 (2006.01); A61K 45/06 (2006.01)
CPC C07D 285/24 (2013.01) [C07D 417/10 (2013.01); A61K 45/06 (2013.01)] 22 Claims
 
1. A compound of Formula 1,

OG Complex Work Unit Chemistry
or a tautomer thereof, or a pharmaceutically acceptable salt of the compound of Formula 1 or tautomer thereof, wherein:
L is selected from a bond and C1-4 alkanediyl;
R1 is selected from
(a) C1-4 alkyl which is substituted with from 0 to 3 optional substituents independently selected from halo, hydroxy, cyano, C1-4 alkoxy, amino and aminocarbonyl, wherein each of the C1-4 alkoxy optional substituents is independently substituted with from 0 to 3 substituents independently selected from halo, and wherein each of the amino and aminocarbonyl optional substituents is independently substituted with from 0 to 2 substituents independently selected from C1-4 alkyl; and
(b) a cyclic group selected from C3-8 cycloalkyl, C2-9 heterocyclyl, C6-14 aryl and C1-9 heteroaryl, wherein the cyclic group is substituted with from 0 to 3 optional substituents independently selected from halo, hydroxy, cyano, C1-4 alkyl, C1-4 alkoxy, amino and aminocarbonyl, wherein each of the C1-4 alkyl and C1-4 alkoxy optional substituents is independently substituted with from 0 to 3 substituents independently selected from halo, and wherein each of the amino and aminocarbonyl optional substituents is independently substituted with from 0 to 2 substituents independently selected from C1-4 alkyl;
R2 is a cyclic group selected from C3-8 cycloalkyl, C2-9 heterocyclyl, C6-14 aryl and C1-9 heteroaryl, wherein the cyclic group is substituted with from 0 to 3 optional substituents independently selected from halo, hydroxy, cyano, C1-4 alkyl, C1-4 alkoxy, amino, C3-8 cycloalkyl and C3-5 heterocyclyl, provided the cyclic group has no more than one optional substituent which is selected from C3-8 cycloalkyl and C3-5 heterocyclyl, and wherein each of the C1-4 alkyl, C1-4 alkoxy, C3-8 cycloalkyl and C3-5 heterocyclyl optional substituents is independently substituted with from 0 to 3 substituents independently selected from halo, and wherein the amino optional substituent is independently substituted with from 0 to 2 substituents independently selected from C1-4 alkyl;
R3, R4, and R5 are each independently selected from hydrogen, halo, cyano, and C1-3 alkyl;
wherein each of the aforementioned heterocyclyl and heteroaryl moieties independently has 1 to 4 heteroatoms as ring members, each independently selected from N, O, and S.